Background and Aim: The first acute-phase protein to be described is called C-reactive protein (CRP), and it is a very sensitive systemic marker of tissue damage, infection, and inflammation. Raised CRP levels have been linked favourably to existing asthma, respiratory impairment, and bronchial hyperresponsiveness. In this investigation, we assessed the connection between the blood CRP level and inflammation among asthmatic patients. Material and Methods: The study's participants were split into two groups: A control group of 50 healthy individuals and 50 asthmatic patients makes up the study group. The best measurements of forced expiratory volume (FEV1) and peak expiratory flow rate (PEFR) were taken using the Spirolab, MIR, and 3 ml of blood was drawn for the assessment of hs-CRP. The serum was separated using the hs-CRP detection kit (nephelometry) by Genrui Biotech. Inc., and in accordance with the protocols, the reference range for the two groups' hs-CRP levels was determined. Results: In comparison to the control group, asthma sufferers' FEV1 and PEFR were significantly lower. When the values of the hs-CRP in the two groups were compared, it was discovered that the study group's value was higher than the control groups. Compared to asthmatic individuals with stable clinical condition, those whose levels were measured after an acute exacerbation had more pronounced hs-CRP elevations. In the current investigation, adult asthmatic patients' hs-CRP levels were considerably greater than those of middle-aged patients. Conclusion: Future studies on the impact on the long-term result may be useful in limiting the undesirable and irreversible changes of asthma. Hs-CRP can be considered a good biomarker for assessing the severity and stability of asthma.